Probiodrug, VU University Medical Center to Assess Alzheimer's Assays | GenomeWeb

NEW YORK (GenomeWeb News) – German biopharmaceutical firm Probiodrug and the VU University Medical Center Alzheimer Center in The Netherlands today announced a collaboration to evaluate molecular biomarker assays for Alzheimer's disease.

The assays will be assessed for their diagnostic, pharmacodynamic, and therapeutic use. Cerebrospinal fluid samples from well-characterized Alzheimer's disease patients at different stages of the illness will be analyzed and compared with CSF from age-matched control samples as part of the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.